title: Ð¡Ð¾Ð·Ð´Ð°Ð½Ð¸Ðµ Ð²Ð°ÐºÑÐ¸Ð½Ð½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð Ñ Ñ Ð¸Ð¼ÐµÑÐ½ÑÐ¼ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð¾Ð¼ Ð´Ð»Ñ Ð¸Ð½Ð´ÑÐºÑÐ¸Ð¸ ÐºÑÐ¾ÑÑ-Ð¿ÑÐ¾ÑÐµÐºÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ Ð¸Ð¼Ð¼ÑÐ½Ð½Ð¾Ð³Ð¾ Ð¾ÑÐ²ÐµÑÐ°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Construction of a vaccine strain of the influenza virus B with chimeric hemagglutinin for inducing a cross-protective immune response
Creators: name: ÐÐ°ÑÐ°Ð½Ð¾Ð², ÐÐ¾Ð½ÑÑÐ°Ð½ÑÐ¸Ð½
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: Ð²Ð¸ÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð°
Ð¶Ð¸Ð²Ð°Ñ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð°Ñ Ð²Ð°ÐºÑÐ¸Ð½Ð°
Ñ Ð¸Ð¼ÐµÑÐ½ÑÐ¹ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½
ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½Ð°Ñ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð°Ñ Ð²Ð°ÐºÑÐ¸Ð½Ð°
influenza virus
live attenuated influenza vaccine
chimeric hemagglutinin
universal influenza vaccine

description: ÐÐ¸ÑÑÑÑ Ð³ÑÐ¸Ð¿Ð¿Ð° ÑÐ²Ð»ÑÑÑÑÑ Ð²Ð¾Ð·Ð±ÑÐ´Ð¸ÑÐµÐ»ÑÐ¼Ð¸ ÑÐµÐ·Ð¾Ð½Ð½ÑÑ Ð¸Ð½ÑÐµÐºÑÐ¸Ð¹. ÐÐ»Ñ Ð·Ð°ÑÐ¸ÑÑ Ð¾Ñ ÑÑÐ¸Ñ Ð¸Ð½ÑÐµÐºÑÐ¸Ð¹ ÑÑÐµÐ±ÑÑÑÑÑ Ð¿Ð¾Ð²ÑÐ¾ÑÐ½ÑÐµ Ð²Ð°ÐºÑÐ¸Ð½Ð°ÑÐ¸Ð¸, Ð¸Ð½Ð´ÑÑÐ¸ÑÑÑÑÐ¸Ðµ Ð¸Ð¼Ð¼ÑÐ½Ð¸ÑÐµÑ Ðº Ð°ÐºÑÑÐ°Ð»ÑÐ½ÑÐ¼ ÑÐ¸ÑÐºÑÐ»Ð¸ÑÑÑÑÐ¸Ð¼ Ð²Ð¸ÑÑÑÐ°Ð¼, Ð² Ð²Ð¸Ð´Ñ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð½ÑÑ Ð¾ÑÐ»Ð¸ÑÐ¸Ð¹ Ð¼ÑÑÐ¸ÑÑÑÑÐ¸Ñ ÑÑÐ°Ð¼Ð¼Ð¾Ð². Ð¦ÐµÐ»ÑÑ Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ ÑÐ²Ð»ÑÐµÑÑÑ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸Ðµ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²Ð°ÐºÑÐ¸Ð½Ð½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° B, Ð¸Ð½Ð´ÑÑÐ¸ÑÑÑÑÐµÐ³Ð¾ ÐºÑÐ¾ÑÑ-Ð¿ÑÐ¾ÑÐµÐºÑÐ¸Ð²Ð½ÑÐ¹ Ð¸Ð¼ÑÐ½Ð½ÑÐ¹ Ð¾ÑÐ²ÐµÑ Ð¿ÑÐ¾ÑÐ¸Ð² Ð²Ð¸ÑÑÑÐ¾Ð² Ð³ÑÐ¸Ð¿Ð¿Ð° B Ð´Ð²ÑÑ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð»Ð¸Ð½Ð¸Ð¹ â Â«ÐÐ¸ÐºÑÐ¾ÑÐ¸ÑÂ» Ð¸ Â«Ð¯Ð¼Ð°Ð³Ð°ÑÐ°Â». Ð¢Ð°ÐºÐ¾Ð¹ ÑÑÑÐµÐºÑ Ð´Ð¾ÑÑÐ¸Ð³Ð°ÐµÑÑÑ Ð·Ð° ÑÑÑÑ Ð¸Ð½Ð´ÑÐºÑÐ¸Ð¸ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ñ Ð½ÐµÐ¹ÑÑÐ°Ð»Ð¸Ð·ÑÑÑÐ¸Ñ Ð°Ð½ÑÐ¸ÑÐµÐ» Ðº Ð±Ð¾Ð»ÐµÐµ ÐºÐ¾Ð½ÑÐµÑÐ²Ð°ÑÐ¸Ð²Ð½ÑÐ¼ Ð°Ð½ÑÐ¸Ð³ÐµÐ½Ð½ÑÐ¼ ÑÐµÐ³Ð¸Ð¾Ð½Ð°Ð¼ Ð² ÑÑÐµÐ±Ð»ÐµÐ²Ð¾Ð¼ Ð´Ð¾Ð¼ÐµÐ½Ðµ Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ½Ð¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ° Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð°. Ð ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ Ð¼ÐµÑÐ¾Ð´Ð°Ð¼Ð¸ Ð³ÐµÐ½Ð½Ð¾Ð¹ Ð¸Ð½Ð¶ÐµÐ½ÐµÑÐ¸Ð¸ Ð¸ Ð¾Ð±ÑÐ°ÑÐ½Ð¾Ð¹ Ð³ÐµÐ½ÐµÑÐ¸ÐºÐ¸ Ð±ÑÐ» Ð¿Ð¾Ð»ÑÑÐµÐ½ Ð²Ð°ÐºÑÐ¸Ð½Ð½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° B, ÑÐ¾Ð´ÐµÑÐ¶Ð°ÑÐ¸Ð¹ ÑÐ¸Ð¼ÐµÑÐ½ÑÐ¹ Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ½ÑÐ¹ Ð±ÐµÐ»Ð¾Ðº Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½ Ñ Ð´Ð¾Ð¼ÐµÐ½Ð°Ð¼Ð¸ Ð¾Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ ÑÑÐ°Ð¼Ð¼Ð¾Ð² Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° B: Ð³Ð¾Ð»Ð¾Ð²Ð½Ð¾Ð¹ Ð¾Ñ B/Brisbane/60/2008 Ð¸ ÑÑÐµÐ±Ð»ÐµÐ²Ð¾Ð¹ Ð¾Ñ B/Phuket/3073/2013. ÐÐµÐ½ NA Ð·Ð°Ð¸Ð¼ÑÑÐ²Ð¾Ð²Ð°Ð½ Ñ B/Brisbane/60/2008, Ð° Ð²Ð½ÑÑÑÐµÐ½Ð½Ð¸Ðµ Ð³ÐµÐ½Ñ Ñ ÑÐ¾Ð»Ð¾Ð´Ð¾Ð°Ð´Ð°Ð¿ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð´Ð¾Ð½Ð¾ÑÐ° Ð°ÑÑÐµÐ½ÑÐ°ÑÐ¸Ð¸ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð° Ð. Ð­ÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Ð±ÑÐ» Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½ in vitro. ÐÐ¾Ð»ÑÑÐµÐ½Ð½ÑÐµ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ ÑÐ²Ð¸Ð´ÐµÑÐµÐ»ÑÑÑÐ²ÑÑÑ Ð¾ Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ÑÑÐ¸ ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ ÑÑÐ°Ð¼Ð¼Ð° Ñ ÑÐ¸Ð¼ÐµÑÐ½ÑÐ¼ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð¾Ð¼, ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÑ ÐºÐ¾ÑÐ¾ÑÐ¾Ð³Ð¾ ÑÐ½Ð°ÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ñ Ð¾Ñ ÑÐ°Ð·Ð½ÑÑ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð»Ð¸Ð½Ð¸Ð¹. Ð Ð¾ÑÑÐ¾Ð²ÑÐµ ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸ÑÑÐ¸ÐºÐ¸ Ð¸ Ð±Ð¸Ð¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ðµ ÑÐ²Ð¾Ð¹ÑÑÐ²Ð° ÑÑÐ°Ð¼Ð¼Ð° Ð´ÐµÐ»Ð°ÑÑ ÐµÐ³Ð¾ Ð¿ÐµÑÑÐ¿ÐµÐºÑÐ¸Ð²Ð½ÑÐ¼ ÐºÐ°Ð½Ð´Ð¸Ð´Ð°ÑÐ¾Ð¼ Ð´Ð»Ñ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½Ð¾Ð¹ Ð¾ÑÐµÐ½ÐºÐ¸ Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ÑÑÐ¸ Ð¸Ð½Ð´ÑÐºÑÐ¸Ð¸ ÐºÑÐ¾ÑÑ-Ð¿ÑÐ¾ÑÐµÐºÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ Ð¸Ð¼ÑÐ½Ð½Ð¾Ð³Ð¾ Ð¾ÑÐ²ÐµÑÐ° Ð¿Ð¾ÑÑÐµÐ´ÑÑÐ²Ð¾Ð¼ Ð¿Ð¾ÑÐ»ÐµÐ´Ð¾Ð²Ð°ÑÐµÐ»ÑÐ½Ð¾Ð¹ Ð²Ð°ÐºÑÐ¸Ð½Ð°ÑÐ¸Ð¸ Ð²Ð°ÐºÑÐ¸Ð½Ð½ÑÐ¼Ð¸ ÑÑÐ°Ð¼Ð¼Ð°Ð¼Ð¸ Ñ Ð¸Ð´ÐµÐ½ÑÐ¸ÑÐ½ÑÐ¼Ð¸ ÑÑÐµÐ±Ð»ÐµÐ²ÑÐ¼Ð¸ Ð´Ð¾Ð¼ÐµÐ½Ð°Ð¼Ð¸ Ð³ÐµÐ¼Ð°Ð³Ð³Ð»ÑÑÐ¸Ð½Ð¸Ð½Ð°.
description: Influenza viruses cause seasonal infections. To protect against such infections regular vaccinations are needed, that induce an immune response specific to the relevant circulating strains due to the antigenic novelty of the mutating influenza strains. The aim of this work is to construct an experimental LAIV strain that induces a cross-protective immune response against influenza B viruses of both genetic lineages â âVictoriaâ and âYamagataâ. To achieve this effect a vaccine strain induces an accumulation of neutralizing antibodies specific to conservative antigenic sites in a stalk domain of a surface protein hemagglutinin. In this study a vaccine strain of IBV was constructed by means of genetic engineering and reverse genetics. The strain has a chimeric hemagglutinin which domains are inherited from the different IBV strains: head domain from B/Brisbane/60/2008 (Victoria-lineage) and stalk domzin from B/Phuket/3073/2013 (Yamagata-lineage). NA segment of this strain was also taken from B/Brisbane/60/2008 and the internal genetic segments from the cold-adapted IBV attenuation donor. The experimental strain was studied in vitro. The results show the success in constructing a strain with such chimeric HA. The growth characteristics and the biological qualities of the experimental strain indicate that it would be a perfect candidate for experimental assessment of inducing the cross-protective immune response in further studies.